12 active not recruiting, 12 recruiting, 11 terminated, 10 completed. 24 Phase 2, 13 Phase 1, 8 Phase 3, 4 Not applicable, 2 Early Phase 1.
Follow Stage IVA Prostate Cancer AJCC v8: new trials by email Literature Review of Stage IVA Prostate Cancer AJCC v8 trials Research Report on Stage IVA Prostate Cancer AJCC v8
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Magnetic Resonance-Guided Stereotactic Body Radiation Therapy for the Treatment of Prostate Cancer Biopsy Procedure, Computed Tomography, Electronic Health Record Review - Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8 | Not applicable | Not yet recruiting | City of Hope Medical Center | 20 | 2027-01-01 | 2026-08-17 |
| REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial Abiraterone Acetate, Bicalutamide, Biospecimen Collection - Recurrent Prostate Carcinoma, Stage III Prostate Cancer AJCC v8 | Phase 3 | Recruiting | Emory University | 72 | 2025-01-31 | 2026-02-24 |
| Accuracy of 18F-rhPSMA-7.3 PET/ MRI for Prediction of Lymph Node Metastasis in Localized High-Risk Prostate Cancer Bilateral Pelvic Lymph Node Dissection, Biospecimen Collection, Bone Scan - Localized Prostate Carcinoma, Oligometastatic Prostate Carcinoma | Not applicable | Recruiting | Mayo Clinic | 50 | 2024-06-11 | 2026-04-06 |
| Image-Guided Biopsies to Identify Mechanisms of Resistance in Patients With Metastatic Castration Resistant Prostate Cancer Treated With 177Lu-PSMA Radioligand Therapy Image Guided Biopsy - Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma | Phase 1 | Recruiting | Jonsson Comprehensive Cancer Center | 30 | 2024-04-26 | 2026-06-15 |
| Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer Biospecimen Collection, Bone Scan, Computed Tomography - Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8 | Phase 3 | Recruiting | NRG Oncology | 1209 | 2023-12-14 | 2026-09-10 |
| Vitamin D for Prostate Endocrine Therapy Biospecimen Collection, D Vitamin, Dual X-ray Absorptiometry - Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8 | Phase 3 | Recruiting | University of Rochester | 240 | 2023-12-14 | 2026-01-15 |
| Time-Restricted Eating Versus Nutritional Counseling for the Reduction of Radiation or Chemoradiation Tx Side Effects in Patients With Prostate, Cervical, or Rectal Cancers Biospecimen Collection, Informational Intervention, Quality-of-Life Assessment - Localized Prostate Carcinoma, Locally Advanced Cervical Carcinoma | Phase 2 | Active not recruiting | City of Hope Medical Center | 49 | 2023-03-23 | 2026-10-20 |
| Gallium-68 PSMA-11 PET in Participants With Prostate Cancer Computed Tomography, Gallium Ga 68-labeled PSMA-11, Magnetic Resonance Imaging - Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma | Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2022-09-26 | 2024-03-07 | |
| Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer Abemaciclib, Lutetium Lu 177-PSMA-617 - Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | Vadim S Koshkin | 30 | 2022-07-08 | 2026-07-24 |
| Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer Atezolizumab, Cabozantinib S-malate - Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma | Phase 2 | Active not recruiting | University of Utah | 31 | 2022-03-29 | 2026-10-14 |
| Decitabine/Cedazuridine and Enzalutamide for the Treatment of Metastatic Castrate Resistant Prostate Cancer Decitabine and Cedazuridine, Enzalutamide - Castration-Resistant Prostate Carcinoma, Stage IV Prostate Cancer AJCC v8 | Phase 1 | Terminated | Roswell Park Cancer Institute | 8 | 2022-01-26 | 2025-11-12 |
| Treatment of Cancer-Related Bone Pain by Using Bone-Targeted Radiation-Based Therapy (Sn-117m-DTPA) in Patients With Prostate Cancer That Has Spread to Bones Questionnaire Administration, Tin Sn 117m Pentetate - Castration-Resistant Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone | Phase 2 | Terminated | National Cancer Institute (NCI) | 1 | 2021-12-18 | 2025-10-03 |
| A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy Enzalutamide, Rucaparib camsylate, Placebo - Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma | Phase 3 | Active not recruiting | Alliance for Clinical Trials in Oncology | 61 | 2021-10-14 | 2026-02-05 |
| Pharmacokinetics of IA and IV Ga68-PSMA-11 Infusion Angiogram, Catheterization, Gallium Ga-labeled PSMA-11 - Prostate Adenocarcinoma, Prostate Carcinoma | Early Phase 1 | Completed | Ryan Kohlbrenner, MD | 5 | 2021-10-13 | 2023-04-07 |
| 68Ga-PSMA-11 PET for the Diagnosis of Metastatic Castration Resistant Prostate Cancer 68Ga-PSMA-11, Positron Emission Tomography (PET) - Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma | Phase 2 | Terminated | Thomas Hope | 15 | 2021-09-28 | 2026-05-15 |
| High Dose-Rate Brachytherapy and Stereotactic Body Radiotherapy for the Treatment of Prostate Adenocarcinoma High-Dose Rate Brachytherapy, Stereotactic Body Radiation Therapy - Prostate Adenocarcinoma, Stage IIB Prostate Cancer American Joint Committee on Cancer (AJCC) v8 | Not applicable | Recruiting | Jonsson Comprehensive Cancer Center | 52 | 2021-08-20 | 2026-08-20 |
| 11C-YJH08 PET Imaging for Detection of Glucocorticoid Receptor Expression Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography - Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma | Phase 1 | Terminated | Rahul Aggarwal | 2 | 2021-08-10 | 2025-05-20 |
| Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer Abiraterone Acetate, Antiandrogen Therapy, Apalutamide - Prostate Carcinoma, Stage IIC Prostate Cancer AJCC v8 | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 200 | 2021-08-05 | 2026-06-23 |
| Erdafitinib for the Treatment of Patients With Castration-Resistant Prostate Cancer Biopsy, Biospecimen Collection, Erdafitinib - Castration-Resistant Prostate Carcinoma, Castration-Resistant Prostate Carcinoma Refractory to Second-Generation Androgen Receptor Axis-Targeted Agents | Phase 2 | Terminated | M.D. Anderson Cancer Center | 11 | 2021-07-15 | 2026-02-06 |
| Extremely Hypofractionated Intensity Modulated Stereotactic Body Radiotherapy for the Treatment of Prostate Cancer With Rising PSA After Radical Prostatectomy Hormone Therapy, Stereotactic Body Radiation Therapy - Prostate Adenocarcinoma, Stage IIIB Prostate Cancer American Joint Committee on Cancer (AJCC) v8 | Phase 2 | Active not recruiting | Jonsson Comprehensive Cancer Center | 165 | 2021-06-23 | 2026-07-17 |
Showing 20 of 50. Sign in to see all of them.
Prostatic Neoplasms (50) · Colorectal Neoplasms (4) · Neoplasm Metastasis (4) · Ovarian Neoplasms (4) · Carcinoma, Renal Cell (3) · Carcinoma, Transitional Cell (2) · Pancreatic Neoplasms (2) · Urogenital Neoplasms (2) · Brain Neoplasms (1) · Breast Neoplasms (1) · Clear-cell metastatic renal cell carcinoma (1) · Gastrointestinal Neoplasms (1) · Lung Neoplasms (1) · Melanoma (1) · Neoplasms (1)
Genital Diseases (50) · Genital Diseases, Male (50) · Genital Neoplasms, Male (50) · Male Urogenital Diseases (50) · Neoplasms by Site (50) · Prostatic Diseases (50) · Urogenital Diseases (50) · Neoplasms (49) · Urogenital Neoplasms (48) · Digestive System Diseases (6) · Digestive System Neoplasms (6) · Female Urogenital Diseases (6) · Female Urogenital Diseases and Pregnancy Complications (6) · Endocrine Gland Neoplasms (5) · Endocrine System Diseases (5)
Magnetic Resonance Spectroscopy (13) · Radiation (10) · Radiotherapy (9) · Specimen Handling (9) · Abiraterone Acetate (7) · Prednisone (7) · Leuprolide (6) · apalutamide (6) · deltacortene (6) · enzalutamide (6) · gallium 68 PSMA-11 (6) · prednylidene (6) · acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide (5) · 68Ga-DKFZ-PSMA-11 (4) · Goserelin (4)
M.D. Anderson Cancer Center (14) · Jonsson Comprehensive Cancer Center (6) · City of Hope Medical Center (5) · NRG Oncology (4) · National Cancer Institute (NCI) (3) · Roswell Park Cancer Institute (3) · Mayo Clinic (2) · Rahul Aggarwal (2) · University of Washington (2) · Alliance for Clinical Trials in Oncology (1) · Emory University (1) · Ryan Kohlbrenner, MD (1) · SWOG Cancer Research Network (1) · Thomas Hope (1) · University of Rochester (1)
United States (49) · Canada (4) · Switzerland (2) · Chile (1) · Colombia (1) · Hong Kong (1) · Mexico (1) · Puerto Rico (1)
Gurkamal Chatta (2) · Jeremie Calais (2) · Paul Corn (2) · Alison M Schram (1) · Amar Kishan (1) · Ana Aparicio (1) · Arpit Rao, MD (1) · Aung Naing (1) · Bagi Jana, MD (1) · Brian Chapin (1) · Christopher J Logothetis (1) · Eleni Efstathiou (1) · Gregory C Ravizzini, MD (1) · Gurkamal S Chatta (1) · Ivan A de Kouchovsky, MD (1)
PMID 41698328, PMID 33602654, PMID 34663638, PMID 35405009, PMID 35428207, PMID 36351402, PMID 37902861, PMID 38421243, PMID 38867077, PMID 39136560, PMID 39254446, PMID 39420060, PMID 40139261, PMID 40377420, PMID 40939237, PMID 41315064, PMID 41646361
P30CA033572 (4), U10CA180868 (4), P30CA014089 (1), P30CA042014 (1), P30CA138292 (1), P50CA097186 (1), R01CA258349 (1), R01MH115043 (1), U10CA180821 (1), U10CA180888 (1), UG1CA189961 (1), UM1CA186691 (1), UM1CA186712 (1)